Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

Alfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Two important response criteria in systemic mastocytosis (SM) are the elimination or reduction in percentage of bone marrow mast cells (MCs) and the reduction of serum tryptase levels. We investigated the accuracy of a single time point reduction of bone marrow MCs and serum tryptase level as response criteria in 50 patients with SM with available serial assessments. Bone marrow MC percentage varied significantly, with an average coefficient of variation (CV) of 65% (range, 6-173%) and 44% of patients having a CV higher than the average. The average CV for serum tryptase level was 19% (range, 0-96%), with 36% of patients having a CV higher than average. These wide variations in bone marrow MC burden and serum tryptase level were independent of the administration of SM-directed therapy, type of therapy or disease subtype. Furthermore, the achievement of a single time point therapy-induced bone marrow complete response (no histological evidence of malignant bone marrow MCs) did not correlate with tryptase level or symptomatic improvement. In conclusion, the value of single measurements of bone marrow MC percentage and serum tryptase level as response criteria in SM is not supported by clinical data. Incorporation of an assessment of the degree in reduction of MCs and tryptase, and assessment of response durability, would make response criteria more clinically meaningful.

Original languageEnglish (US)
Pages (from-to)1959-1964
Number of pages6
JournalLeukemia and Lymphoma
Volume54
Issue number9
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Systemic Mastocytosis
Tryptases
Mast Cells
Bone Marrow Cells
Serum
Therapeutics
Bone Marrow

Keywords

  • Mast cell burden
  • Response criteria
  • Systemic mastocytosis
  • Tryptase

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. / Quintás-Cardama, Alfonso; Sever, Matjaz; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan.

In: Leukemia and Lymphoma, Vol. 54, No. 9, 01.09.2013, p. 1959-1964.

Research output: Contribution to journalArticle

Quintás-Cardama, Alfonso ; Sever, Matjaz ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan. / Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 9. pp. 1959-1964.
@article{1a3478c2b77f47b3afb33c35cce78168,
title = "Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis",
abstract = "Two important response criteria in systemic mastocytosis (SM) are the elimination or reduction in percentage of bone marrow mast cells (MCs) and the reduction of serum tryptase levels. We investigated the accuracy of a single time point reduction of bone marrow MCs and serum tryptase level as response criteria in 50 patients with SM with available serial assessments. Bone marrow MC percentage varied significantly, with an average coefficient of variation (CV) of 65{\%} (range, 6-173{\%}) and 44{\%} of patients having a CV higher than the average. The average CV for serum tryptase level was 19{\%} (range, 0-96{\%}), with 36{\%} of patients having a CV higher than average. These wide variations in bone marrow MC burden and serum tryptase level were independent of the administration of SM-directed therapy, type of therapy or disease subtype. Furthermore, the achievement of a single time point therapy-induced bone marrow complete response (no histological evidence of malignant bone marrow MCs) did not correlate with tryptase level or symptomatic improvement. In conclusion, the value of single measurements of bone marrow MC percentage and serum tryptase level as response criteria in SM is not supported by clinical data. Incorporation of an assessment of the degree in reduction of MCs and tryptase, and assessment of response durability, would make response criteria more clinically meaningful.",
keywords = "Mast cell burden, Response criteria, Systemic mastocytosis, Tryptase",
author = "Alfonso Quint{\'a}s-Cardama and Matjaz Sever and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",
year = "2013",
month = "9",
day = "1",
doi = "10.3109/10428194.2012.763121",
language = "English (US)",
volume = "54",
pages = "1959--1964",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

AU - Quintás-Cardama, Alfonso

AU - Sever, Matjaz

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Two important response criteria in systemic mastocytosis (SM) are the elimination or reduction in percentage of bone marrow mast cells (MCs) and the reduction of serum tryptase levels. We investigated the accuracy of a single time point reduction of bone marrow MCs and serum tryptase level as response criteria in 50 patients with SM with available serial assessments. Bone marrow MC percentage varied significantly, with an average coefficient of variation (CV) of 65% (range, 6-173%) and 44% of patients having a CV higher than the average. The average CV for serum tryptase level was 19% (range, 0-96%), with 36% of patients having a CV higher than average. These wide variations in bone marrow MC burden and serum tryptase level were independent of the administration of SM-directed therapy, type of therapy or disease subtype. Furthermore, the achievement of a single time point therapy-induced bone marrow complete response (no histological evidence of malignant bone marrow MCs) did not correlate with tryptase level or symptomatic improvement. In conclusion, the value of single measurements of bone marrow MC percentage and serum tryptase level as response criteria in SM is not supported by clinical data. Incorporation of an assessment of the degree in reduction of MCs and tryptase, and assessment of response durability, would make response criteria more clinically meaningful.

AB - Two important response criteria in systemic mastocytosis (SM) are the elimination or reduction in percentage of bone marrow mast cells (MCs) and the reduction of serum tryptase levels. We investigated the accuracy of a single time point reduction of bone marrow MCs and serum tryptase level as response criteria in 50 patients with SM with available serial assessments. Bone marrow MC percentage varied significantly, with an average coefficient of variation (CV) of 65% (range, 6-173%) and 44% of patients having a CV higher than the average. The average CV for serum tryptase level was 19% (range, 0-96%), with 36% of patients having a CV higher than average. These wide variations in bone marrow MC burden and serum tryptase level were independent of the administration of SM-directed therapy, type of therapy or disease subtype. Furthermore, the achievement of a single time point therapy-induced bone marrow complete response (no histological evidence of malignant bone marrow MCs) did not correlate with tryptase level or symptomatic improvement. In conclusion, the value of single measurements of bone marrow MC percentage and serum tryptase level as response criteria in SM is not supported by clinical data. Incorporation of an assessment of the degree in reduction of MCs and tryptase, and assessment of response durability, would make response criteria more clinically meaningful.

KW - Mast cell burden

KW - Response criteria

KW - Systemic mastocytosis

KW - Tryptase

UR - http://www.scopus.com/inward/record.url?scp=84882995926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882995926&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.763121

DO - 10.3109/10428194.2012.763121

M3 - Article

C2 - 23278641

AN - SCOPUS:84882995926

VL - 54

SP - 1959

EP - 1964

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 9

ER -